BioCardia, Inc. (NASDAQ:BCDA) Q2 2025 Earnings Convention Name August 11, 2025 7:00 AM ET
Firm Contributors
David McClung – Chief Monetary Officer
Miranda Peto Benvenuti – Company Participant
Peter A. Altman – CEO, President & Director
Convention Name Contributors
James Francis Molloy – Alliance International Companions, Analysis Division
Kumaraguru Raja – Brookline Capital Markets, LLC, Analysis Division
Lander Egaña-Gorroño – H.C. Wainwright & Co, LLC, Analysis Division
Operator
Girls and gents, thanks for standing by. Good afternoon, and welcome to the BioCardia Second Quarter Monetary Outcomes and Enterprise Replace Convention name. [Operator Instructions] Contributors of this name are suggested that the audio of this convention name is being broadcast reside over the Web and can also be being recorded for playback functions. A webcast replay of the decision might be accessible roughly 1 hour after the top of the decision.
I might now like to show the decision over to Miranda Peto of BioCardia Investor Relations. Please go forward, Miranda.
Miranda Peto Benvenuti
Thanks very a lot. Good afternoon, and thanks all for collaborating in right now’s convention name. Becoming a member of me from BioCardia’s management staff are Peter Altman, President and Chief Govt Officer; and David McClung, the corporate’s Chief Monetary Officer.
Throughout this name, administration might be making forward-looking statements together with statements that deal with BioCardia’s expectations for future efficiency and operational outcomes, references to administration’s intentions, beliefs, projections, outlook, analyses and present expectations. These elements embody, amongst others, the inherent uncertainties related to creating new merchandise applied sciences and acquiring regulatory approvals. Ahead-looking statements contain dangers and different elements which will trigger precise outcomes to vary materially from these statements. For extra details about these dangers, please confer with the Danger Components and cautionary statements described in BioCardia’s report on Kind 10-Okay filed with the SEC on March 26, 2025, and in subsequently filed stories on Kind 10-Q.
